Literature DB >> 20805169

Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008.

Elizabeth Koshy1, Joanna Murray, Alex Bottle, Mike Sharland, Sonia Saxena.   

Abstract

BACKGROUND: Childhood bacterial pneumonia and empyema rates have reportedly increased in recent years in Europe. In September 2006 the seven-valent pneumococcal conjugate vaccination (PCV7) was introduced to the childhood national immunisation programme in England following a successful PCV7 campaign in the USA. The aim of this study was to report national time trends in hospital admissions for childhood bacterial pneumonia and empyema in England before and after the introduction of PCV7.
METHODS: A population-based time-trend analysis of Hospital Episode Statistics data of children aged <15 years admitted to all NHS hospitals in England, with a primary diagnosis of bacterial pneumonia and empyema from 1997 to 2008 was performed. Annual crude and age-sex standardised hospital admission rates for bacterial pneumonia and empyema were calculated.
RESULTS: Admission rates for bacterial pneumonia and empyema increased from 1997 to 2006, then declined to 2008. Bacterial pneumonia rates decreased to 1079 (95% CI 1059 to 1099) per million children and empyema rates decreased to 14 (95% CI 11 to 16) per million children. The RR for bacterial pneumonia admissions was 1.19 (95% CI 1.16 to 1.22) in 2006 compared with 2004 and 0.81 (95% CI 0.79 to 0.83) in 2008 compared with 2006. For empyema, the corresponding RRs were 1.77 (95% CI 1.38 to 2.28) in 2006 compared with 2004 and 0.78 (95% CI 0.62 to 0.98) in 2008 compared with 2006.
CONCLUSION: Childhood bacterial pneumonia and empyema admission rates were increasing prior to 2006 and decreased by 19% and 22% respectively between 2006 and 2008, following the introduction of the PCV7 pneumococcal conjugate vaccination to the national childhood immunisation programme.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20805169     DOI: 10.1136/thx.2010.137802

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  38 in total

Review 1.  The impact of new vaccine introduction on immunization and health systems: a review of the published literature.

Authors:  Terri B Hyde; Holly Dentz; Susan A Wang; Helen E Burchett; Sandra Mounier-Jack; Carsten F Mantel
Journal:  Vaccine       Date:  2012-08-29       Impact factor: 3.641

2.  Decline in early childhood respiratory tract infections in the Norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccination.

Authors:  Maria C Magnus; Didrik F Vestrheim; Wenche Nystad; Siri Eldevik Håberg; Hein Stigum; Stephanie J London; Marianne A R Bergsaker; Dominique A Caugant; Ingeborg S Aaberge; Per Nafstad
Journal:  Pediatr Infect Dis J       Date:  2012-09       Impact factor: 2.129

3.  Routine infant vaccination of pneumococcal conjugate vaccines has decreased pneumonia across all age groups in Northern Spain.

Authors:  I Rivero-Calle; J Pardo Seco; P F Raguindin; F Alvez; J Gómez-Rial; A Salas; J Martinón Sanchez; F Martinón-Torres
Journal:  Hum Vaccin Immunother       Date:  2019-12-18       Impact factor: 3.452

4.  Changes in empyema among U.S. children in the pneumococcal conjugate vaccine era.

Authors:  Andrew D Wiese; Marie R Griffin; Yuwei Zhu; Edward F Mitchel; Carlos G Grijalva
Journal:  Vaccine       Date:  2016-11-07       Impact factor: 3.641

Review 5.  Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.

Authors:  Katelijne van de Vooren; Silvy Duranti; Alessandro Curto; Livio Garattini
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

6.  A retrospective analysis of hospital discharge records for S. pneumoniae diseases in the elderly population of Florence, Italy, 2010-2012.

Authors:  Angela Bechini; Cristina Taddei; Alessandro Barchielli; Miriam Levi; Emilia Tiscione; Maria Grazia Santini; Fabrizio Niccolini; Maria Teresa Mechi; Donatella Panatto; Daniela Amicizia; Chiara Azzari; Paolo Bonanni; Sara Boccalini
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

7.  Increased paediatric hospitalizations for empyema in Australia after introduction of the 7-valent pneumococcal conjugate vaccine.

Authors:  Roxanne E Strachan; Thomas L Snelling; Adam Jaffé
Journal:  Bull World Health Organ       Date:  2012-12-11       Impact factor: 9.408

8.  U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination.

Authors:  Marie R Griffin; Yuwei Zhu; Matthew R Moore; Cynthia G Whitney; Carlos G Grijalva
Journal:  N Engl J Med       Date:  2013-07-11       Impact factor: 91.245

9.  The relevance of pneumococcal serotypes.

Authors:  Chamira Rodrigo; Wei Shen Lim
Journal:  Curr Infect Dis Rep       Date:  2014-04       Impact factor: 3.725

10.  Carers' perspectives on the presentation of community-acquired pneumonia and empyema in children: a case series.

Authors:  Joanna C Crocker; Meirion R Evans; Christopher C Butler; Kerenza Hood; Colin V E Powell
Journal:  BMJ Open       Date:  2012-09-04       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.